China Resources Pharmaceuticals' 2H results beat expectations, with resilient manufacturing business and continued M&A focus

Overview

This report is Goldman Sachs' earnings review of China Resources Pharmaceuticals 3320.HK. The company's 2H results beat expectations in a weak industry environment, mainly driven by manufacturing business growth, prescription outflow to retail pharmacies, gross margin improvement, lower financing costs, and a materially lower effective tax rate. The report also highlights that during the 15th Five-Year Plan period the company will continue to use a dual engine of external expansion plus organic development, strengthening its core industrial chain through M&A and investment while cultivating a second growth curve.

Core views

The key views are as follows: first, both 2H revenue and core earnings were better than expected, with manufacturing business as the main source of the beat; second, CSO, medical devices, senior health, high-end equipment, and synthetic biology are positioned as medium-term growth drivers; third, M&A remains a core competitive advantage, with the strategy focused on strengthening, consolidating, supplementing, and extending the industrial chain; fourth, subsidiaries are differentiated in positioning but aligned in direction, advancing integration, category upgrades, and innovation around brand, channel, or technology advantages; fifth, although earnings forecasts and the target price were raised, Goldman Sachs maintains a Neutral rating because the target price implies only 4.4% upside from the current share price.

Analysis framework

The report combines earnings decomposition, growth analysis by business line, subsidiary operating comparisons, and sum-of-the-parts valuation. On the operating side, it focuses on the revenue and profit contributions of manufacturing, distribution, retail, and CSO businesses; on the valuation side, it values manufacturing, distribution, and group expenses separately before aggregating them into a 12-month target price.

Methodology notes

• Valuation methodsSum-of-the-parts valuation

  Value each business segment using exit P/E multiples

  The HK$6.03 target price comes from a sum-of-the-parts valuation: the manufacturing business is valued at Rmb34.8bn, using a 9x 5-year exit P/E and based on 5-year EPS CAGR of 9%; the distribution business is valued at Rmb10.7bn, using a 5x 5-year exit P/E and based on 5-year EPS CAGR of 5%; group expenses are valued at negative Rmb10.7bn, using a 6x 5-year exit P/E and based on 5-year CAGR of 6%.

• Rating frameworkGoldman Sachs Neutral Rating Framework

  Relative total return potential versus the coverage universe

  Goldman Sachs classifies stocks that are not in the Buy or Sell investment list and are still under active coverage as Neutral. China Resources Pharmaceuticals' target price implies only 4.4% upside versus the current price, so the Neutral rating is maintained.

• M&A analysisM&A Rank

  Classification of acquisition-target probability

  The report discloses an M&A Rank of 3 for China Resources Pharmaceuticals, indicating a low probability of becoming an acquisition target, typically 0%-15%, with limited impact from M&A factors on the target price.

• Factor frameworkGS Factor Profile

  Growth, financial returns, valuation multiples, and composite percentile comparison

  Goldman Sachs' factor framework compares a stock against the market and industry peers using sales, EBITDA, and EPS growth; ROE, ROCE, and CROCI; as well as P/E, P/B, dividend yield, and EV/EBITDA metrics.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• China Resources Pharmaceuticals (3320.HK)

  Core coverage name

  Strengths

  2H revenue and earnings beat expectations; manufacturing growth was resilient; retail was supported by prescription outflow; financing costs and tax rates fell; and the M&A strategy was coherent.

  Weaknesses

  Target price upside is only 4.4%; industry conditions are still weak; some OTC, infusion, and chronic-disease categories remain under pressure.

  Comparison

  Compared with the coverage universe, Goldman Sachs assigns a Neutral rating; in valuation, manufacturing is assigned a 9x 5-year exit P/E and distribution a 5x 5-year exit P/E.

  Risks

  Slower growth at manufacturing subsidiaries, wider impact from volume-based procurement, and a weaker-than-expected recovery in the distribution business.

• CR Sanjiu

  Major manufacturing subsidiary

  Strengths

  The CHC strategy remains the core growth engine, with 4Q25 revenue up 22% y/y and net profit up 162% y/y.

  Weaknesses

  Integration of KPC Pharma and Tasly remains a key task, and near-term performance is pressured by Chinese medicine volume-based procurement and channel reform.

  Comparison

  Among the major manufacturing subsidiaries, CR Sanjiu posted particularly strong 4Q25 profit growth.

  Risks

  Integration progress, channel reform, and pressure from Chinese medicine volume-based procurement.

• Dong-E E-Jiao

  Platform for Chinese medicine and ejiao products

  Strengths

  4Q25 revenue rose 43% y/y; product diversification in ejiao continued to grow steadily, and Ejiao Syrup has been included in eight clinical guidelines.

  Weaknesses

  Profit growth lagged revenue growth, and earnings leverage still needs to be observed.

  Comparison

  Revenue growth was stronger than that of other subsidiaries, while net profit grew 15% y/y.

  Risks

  Consumer demand, the effectiveness of category upgrades, and brand conversion efficiency.

• Boya Biopharm

  Blood products platform

  Strengths

  Blood products expansion remains a strategic priority, with plasma station construction concentrated in Jiangxi and Anhui and further regional expansion planned.

  Weaknesses

  4Q25 net profit was affected by impairment and amortization related to the GreenCross acquisition, and blood product margins declined due to procurement and competition.

  Comparison

  Revenue grew 19% y/y, but net profit was under明显 pressure.

  Risks

  Impairment and amortization, volume-based procurement, intensified competition, and slower-than-expected plasma source expansion.

• CSO business

  New commercialization platform and potential growth driver

  Strengths

  FY25 scale exceeded Rmb6bn, roughly doubling y/y, and management guided about 50% growth in 2026.

  Weaknesses

  The sustainability of profitability for this scaled commercial innovation platform still needs to be validated.

  Comparison

  Compared with traditional distribution, CSO is positioned by management as a new driver with stronger commercial innovation characteristics.

  Risks

  Project execution and negotiations, multinational pharma partnerships, and the buildout of academic promotion capabilities.

Key data

• 2H salesRmb137.7bnUp 6.7% y/y and above Goldman Sachs' forecast of 3.7%.
• 2H core earningsRmb2.34bnUp 44% y/y and above Goldman Sachs' original estimate of Rmb1.3bn.
• Manufacturing business revenue growth+15.5% y/yChinese medicine grew 17%, and nutrition and health products grew 54%.
• Retail business revenue growth+30% y/ySupported by prescription outflow to DTP pharmacies.
• Distribution business revenue growth+4% y/yShowed resilience against a weak industry backdrop.
• Gross margin16.7%Above 15.3% in 2H24, driven by a higher mix of high-margin manufacturing business.
• Effective tax rate15%Below 28% in 2H24, as more subsidiaries benefited from tax incentives.
• CSO scaleRmb6bn+FY25 was roughly double y/y, and management guided 2026 growth of about 50%.
• 12-month target priceHK$6.03Raised from HK$5.37 previously.
• Current price and upsideHK$5.78 / 4.4%Price is the 2026-03-31 close.
• Market capHK$36.3bn / US$4.6bnFrom the report's financial summary table.
• Enterprise valueHK$154.4bn / US$19.7bnFrom the report's financial summary table.

Impact & implications

The earnings beat and upward revisions to estimates reinforce the market's recognition of China Resources Pharmaceuticals' manufacturing resilience, tax optimization, and M&A integration capabilities. In the medium term, if the company can continue executing investments and integrations in CSO, blood products, medical devices, senior health, innovative biologics, and synthetic biology, it may improve growth prospects and valuation support. However, the limited upside implied by the current target price suggests that positive factors have already been largely reflected, leaving the investment implication tilted Neutral.

Risks

• Upside risk: stronger-than-expected growth in medical device distribution.
• Upside risk: better-than-expected M&A synergies.
• Downside risk: slower-than-expected growth at manufacturing subsidiaries.
• Downside risk: a wider impact from volume-based procurement.
• Downside risk: a weaker industry recovery leading to slower-than-expected distribution growth.
• Downside risk: subsidiary integration, impairment, or amortization costs weighing on profits.

What to watch

• Whether 2026 revenue growth can continue to outpace the industry average.
• Whether manufacturing gross margin and product mix continue to improve.
• Whether the effective tax rate can be maintained at around 20% or lower.
• The delivery of the 2026 CSO growth guidance of about 50%.
• The integration progress of KPC Pharma and Tasly by CR Sanjiu.
• Boya Biopharm's plasma station expansion, blood product margins, and product launch pace.
• Progress in extending medical devices from commercial distribution into industrial manufacturing.
• Whether future M&A and investment focus on strategically adjacent areas such as blood products, vaccines, innovative biologics, siRNA, gene therapy, and cell therapy.